Search OCGN
Ocugen, Inc.
Nasdaq · CIK 1372299
Last close1.02
Daily change+0.02 (2.00%)
10 Years gain-99.45%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
OCGN · STANDARD
SIC 2836 · Biological Products, (No Diagnostic Substances) · Fiscal year end 1231
Fundamental
47.3Momentum
100.0Acceleration
100.0Confidence
75.0Annual Revenue12
Quarterly Revenue34
Annual CFO9
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth22.4 / 25
Quality12.5 / 25
Capital Efficiency0.0 / 20
Balance Sheet10.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Operating leverageOperating margin improved by 92.2792 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Warnings
Heavy share dilution · HIGHDiluted share count increased 15.9876%.
Key Metrics
Revenue Growth TTM28.79%OK
Revenue CAGR 3Y21.05%OK
Gross Margin100%OK
Operating Margin-1,069.04%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y15.99%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $4.41M | $4.41M | -$62.92M | -$56.96M | -$57.15M | 100% | -1,425.7% | -1,295.01% | n/a | n/a |
| 2025 FY Dec 31, 2024 | $4.06M | $4.06M | -$54.76M | -$42.14M | -$45.53M | 100% | -1,350.36% | -1,122.74% | -2,556.62% | n/a |
| 2024 FY Dec 31, 2023 | $6.04M | $6.04M | -$65.53M | -$62.05M | -$72.53M | 100% | -1,085.67% | -1,201.62% | n/a | n/a |
| 2023 FY Dec 31, 2022 | $2.49M | $2.49M | -$89.07M | -$60.08M | -$64.54M | 100% | -3,580.02% | -2,593.89% | n/a | 214.6M |
| 2022 FY Dec 31, 2021 | n/a | $0.00 | -$58.03M | -$47.94M | -$48.88M | n/a | n/a | n/a | n/a | 195.01M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $6.15M | sum latest 4 fiscal quarters Revenue | OK | 0001628280-26-054057, 0001372299-25-000013 |
| Revenue Growth TTM | 28.79% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001628280-26-054057, 0001372299-25-000013 |
| Revenue CAGR 3Y | 21.05% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001628280-26-014435 |
| Revenue CAGR 5Y | 152.5% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001628280-26-014435 |
| Gross Profit CAGR 3Y | 21.05% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001628280-26-014435 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001628280-26-054057, 0001372299-25-000013 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 100% | Gross Profit / Revenue | OK | 0001628280-26-054057, 0001372299-25-000013 |
| Operating Margin | -1,069.04% | Operating Income / Revenue | OK | 0001628280-26-054057, 0001372299-25-000013 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001628280-26-054057 |
| Current Ratio | 0.8x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 57.2x | (Cash + Short-term Investments) / Total Debt | OK | 0001628280-26-054057 |
| Revenue per Diluted Share | $0.02 | Revenue / Diluted Shares | OK | 0001628280-26-054057, 0001372299-25-000013 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |